A methylation risk score for chronic kidney disease: a HyperGEN study
- PMID: 39085340
- PMCID: PMC11291488
- DOI: 10.1038/s41598-024-68470-z
A methylation risk score for chronic kidney disease: a HyperGEN study
Abstract
Chronic kidney disease (CKD) impacts about 1 in 7 adults in the United States, but African Americans (AAs) carry a disproportionately higher burden of disease. Epigenetic modifications, such as DNA methylation at cytosine-phosphate-guanine (CpG) sites, have been linked to kidney function and may have clinical utility in predicting the risk of CKD. Given the dynamic relationship between the epigenome, environment, and disease, AAs may be especially sensitive to environment-driven methylation alterations. Moreover, risk models incorporating CpG methylation have been shown to predict disease across multiple racial groups. In this study, we developed a methylation risk score (MRS) for CKD in cohorts of AAs. We selected nine CpG sites that were previously reported to be associated with estimated glomerular filtration rate (eGFR) in epigenome-wide association studies to construct a MRS in the Hypertension Genetic Epidemiology Network (HyperGEN). In logistic mixed models, the MRS was significantly associated with prevalent CKD and was robust to multiple sensitivity analyses, including CKD risk factors. There was modest replication in validation cohorts. In summary, we demonstrated that an eGFR-based CpG score is an independent predictor of prevalent CKD, suggesting that MRS should be further investigated for clinical utility in evaluating CKD risk and progression.
Keywords: Chronic kidney disease; Epigenetics; Methylation risk score; eGFR.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- Prevention, C. F. D. C. a. Chronic Kidney Disease in the United States, 2021. (Atlanta, GA, 2021).
-
- System, U. S. R. D. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD).
MeSH terms
Grants and funding
- P30 ES010126/ES/NIEHS NIH HHS/United States
- R01 ES020836/ES/NIEHS NIH HHS/United States
- T32 DK116672/DK/NIDDK NIH HHS/United States
- F31DK128990/DK/NIDDK NIH HHS/United States
- R01 DK117445/DK/NIDDK NIH HHS/United States
- R01 HL163972/HL/NHLBI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- K24 HL133373/HL/NHLBI NIH HHS/United States
- R35 HL155466/HL/NHLBI NIH HHS/United States
- R01 HG013163/HG/NHGRI NIH HHS/United States
- T32DK116672/DK/NIDDK NIH HHS/United States
- R01HL055673/HL/NHLBI NIH HHS/United States
- R01ES020836/ES/NIEHS NIH HHS/United States
- K26 DK138425/DK/NIDDK NIH HHS/United States
- R35HL155466/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous